A neurofibroma is a benign tumor that grows along peripheral nerves, built primarily from Schwann cells (the cells that insulate nerve fibers), along with fibroblasts, blood vessels, and immune cells. Most neurofibromas arise in people with neurofibromatosis type 1 (NF1), an inherited condition affecting roughly 1 in 3,000 births, though they can also appear sporadically in people without NF1. Despite being classified as benign, these tumors range from small, painless skin bumps to massive internal growths that compress organs, cause chronic pain, and carry a risk of transforming into aggressive cancers.
How Neurofibromas Form
Neurofibromas originate from a genetic disruption in the NF1 gene on chromosome 17, which encodes a protein called neurofibromin. This protein acts as a brake on a cell-growth signaling pathway. When both copies of the NF1 gene are lost or inactivated in a Schwann cell, that brake releases, and the cell begins to proliferate. Research has shown that this unleashed signaling can actually drive mature, myelinated Schwann cells to revert to a less specialized state, setting the stage for tumor formation.1Taylor & Francis Online (Cell Cycle). Ras/Raf/ERK signalling and NF1
NF1 is inherited in an autosomal dominant pattern, meaning a child needs only one faulty copy to develop the condition. But the NF1 gene has one of the highest mutation rates in the human genome, and about half of all cases arise from brand-new mutations rather than being inherited from a parent.2PubMed. Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father This is why many children with NF1 have no family history of the disease.
Mosaicism adds another layer of complexity. In some cases, a mutation occurs early in embryonic development, so only some of the person’s cells carry the faulty gene. One study documented a clinically normal father who carried the NF1 deletion in about 10% of his sperm cells but had no detectable abnormality in his blood cells, yet still transmitted the condition to two children.3PubMed. Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father Somatic mosaicism has also been demonstrated directly in NF1 patients, where different tissues carry different proportions of the mutation, which can explain why some people develop tumors confined to one body region while others have widespread disease.4Journal of Investigative Medicine. Somatic mosaicism for NF1 gene deletion in neurofibromatosis type
The Different Types
Not all neurofibromas behave the same way, and the distinctions matter for prognosis and treatment. The two main categories are cutaneous neurofibromas and plexiform neurofibromas, though pathologists also recognize diffuse and atypical subtypes. Distinguishing among them is not always straightforward, and even experienced pathologists disagree on borderline cases, particularly when a tumor involving the skin lacks clear intraneural features that would mark it as plexiform.5Neuro-Oncology Advances. Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromas
Cutaneous neurofibromas are the most common type. They appear as soft, flesh-colored or slightly pigmented bumps on or just under the skin. They tend to emerge during puberty and continue developing throughout adulthood. While they almost never become malignant, they can number in the hundreds or thousands and are often the most visible and bothersome feature of NF1.6PubMed Central. Dermatologic Manifestations of Neurofibromatosis Type 1 and Emerging Treatments They can itch, cause pain when pressed, and catch on clothing or jewelry.
Plexiform neurofibromas are a different clinical challenge. These grow along the length of a nerve and its branches, sometimes infiltrating surrounding tissue in a way that has been described as feeling like a “bag of worms” under the skin. They are typically congenital or develop in early childhood. About half of all NF1 patients develop at least one plexiform neurofibroma.7PubMed Central. The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma Their growth is fastest in children and young adults; one study of 52 patients found that those aged 21 and younger had the highest progression rates, and for every additional year of age, the average growth rate dropped measurably.8PubMed Central. Growth behavior of plexiform neurofibromas after surgery Unlike cutaneous neurofibromas, plexiform tumors carry a real risk of malignant transformation.
What Is Happening Inside the Tumor
A neurofibroma is not just a mass of rogue Schwann cells. It is a complex ecosystem of multiple cell types, and the immune system plays a surprisingly active role. A hallmark feature is the infiltration of mast cells, which are drawn into the tumor by a chemical signal called stem cell factor (SCF) released by the Schwann cells themselves.9PubMed Central. Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis For years, researchers suspected that removing mast cells might slow tumor growth. But experimental work showed that eliminating the main SCF source, and with it most of the mast cells, only slightly affected tumor progression. The tumors still contained high levels of macrophages regardless of mast cell status, pointing to a broader inflammatory process sustaining the tumor.10PubMed Central. Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis
The picture that has emerged is one of ongoing active inflammation within every neurofibroma. The non-Schwann cell components of the tumor are not just bystanders. Research has implicated the blood-forming system itself in tumor progression, with experiments showing that the NF1 mutation in bone marrow-derived cells, combined with signaling through a receptor called c-kit, is both required and sufficient for tumors to keep growing.11PubMed Central. Mast cells and the neurofibroma microenvironment This complexity explains why targeting any single cell type or pathway has proven insufficient.
Quality of Life and Psychosocial Burden
Cutaneous neurofibromas are among the most common reasons NF1 patients seek medical treatment, and the motivation is not usually fear of cancer. It is disfigurement, discomfort, and the social toll of living with a visible skin condition.12PubMed Central. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1 Studies consistently show that quality of life worsens as the number of tumors increases, and even individuals with fewer than 10 cutaneous neurofibromas report a measurable decrease in well-being. The presence of neurofibromas on the face has a particularly large impact.13JAMA Dermatology. Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1
The psychological effects run deeper than cosmetic distress. One study found that NF1 patients with cutaneous neurofibromas had higher levels of anxiety compared to a control population, with the visibility of tumors and the presence of itch both independently predicting worse quality of life across multiple measurement tools. The questions that scored highest on quality-of-life surveys were about worry over worsening skin disease and embarrassment.14PubMed Central. The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1 Plexiform neurofibromas carry their own quality-of-life burden, distinct enough that a dedicated measurement tool, the PlexiQoL, was developed specifically for adults with these tumors. Its validation confirmed excellent reliability and sensitivity to differences in how patients perceive their tumor severity and general health.15PubMed Central. The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas
When Neurofibromas Turn Malignant
The most feared complication of NF1 is the transformation of a plexiform neurofibroma into a malignant peripheral nerve sheath tumor (MPNST). This occurs in a meaningful fraction of NF1 patients over their lifetime, and MPNSTs are aggressive cancers with high mortality rates. The transformation pathway typically runs from benign plexiform neurofibroma through a borderline stage called an atypical neurofibroma before becoming fully malignant.16PubMed Central. Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors
At the molecular level, the shift from benign to malignant involves complex changes in the activity of many different genes rather than a single unifying switch. Researchers comparing tumor pairs from the same patients found that kinases involved in regulating cell division were particularly enriched among the genes that changed expression during transformation. Some of these showed increased activity in the malignant tumors, making them potential targets for drugs called kinase inhibitors.17PubMed. Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation The heterogeneity of these changes, though, is part of what makes MPNSTs so difficult to treat. There is no single molecular target that reliably distinguishes all malignant tumors from benign ones.
Imaging and Surveillance
Catching malignant transformation early matters, and imaging is the primary surveillance tool. Whole-body MRI is recommended for monitoring internal plexiform neurofibromas, especially in children, where early detection of growth and potential complications helps guide treatment timing.18PubMed Central. Management of plexiform neurofibromas in neurofibromatosis type 1: An Italian Delphi consensus For younger patients, high-resolution ultrasound offers a radiation-free way to detect and track peripheral nerve tumors, which is especially valuable given the need for repeated imaging over many years.19PubMed Central. Role of high-resolution ultrasound in detection and monitoring of peripheral nerve tumor burden in neurofibromatosis in children
When the clinical concern shifts from monitoring growth to ruling out malignancy, PET scanning with a radioactive glucose tracer becomes the key tool. Malignant tumors metabolize glucose at higher rates than benign ones, and studies have consistently shown that the glucose uptake values (SUV) in MPNSTs are significantly higher than in benign plexiform neurofibromas.20PubMed. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI One prospective trial found that while there was overlap between benign and malignant uptake values, all malignant lesions showed uptake above a certain threshold.21PubMed Central. Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Combined PET/MRI offers the advantage of pairing metabolic information with the anatomical detail MRI provides, and studies have shown that standard MRI features like contrast enhancement and certain classic appearance patterns did not reliably differ between benign and malignant tumors, reinforcing the need for the metabolic data PET provides.22PubMed. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI
Surgery and Its Complications
For decades, surgery was essentially the only treatment for symptomatic neurofibromas. It remains important, but it comes with real challenges. Plexiform neurofibromas tend to infiltrate surrounding tissue and wrap around blood vessels in ways that make clean removal difficult. Achieving hemostasis during these operations is technically demanding; electrocautery alone is often insufficient for medium and large vessels because the tumor grows into the vessel walls, preventing isolation.23JPRAS Open. Surgical management of a plexiform neurofibroma in neurofibromatosis type 1: The haemostatic challenge
Tumor size, anatomical location, and history of prior surgery all increase bleeding risk. One retrospective study found that neurofibromas longer than 13 cm were associated with significantly higher rates of needing blood transfusion.24JPRAS Open. Surgical management of a plexiform neurofibroma in neurofibromatosis type 1: The haemostatic challenge The clinical takeaway is that earlier intervention, when tumors are smaller and have not yet deformed surrounding structures, reduces blood loss and operative complexity.25PubMed Central. Risk factors for intraoperative hemorrhage of Type I neurofibromatosis Head and face neurofibromas are particularly high-risk surgical targets, requiring careful preoperative planning and blood preparation.
Selumetinib and the Shift Toward Medical Therapy
The approval of selumetinib in 2020 marked a turning point. This oral drug blocks a protein called MEK, which sits in the same cell-growth signaling pathway that goes haywire when neurofibromin is lost. A phase 1 trial in children with inoperable plexiform neurofibromas showed confirmed tumor shrinkage in 17 of 24 patients (about 71%), with no disease progression observed and anecdotal evidence of decreased pain and improved function.26PubMed Central. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas A subsequent phase 2 trial confirmed these results, with 70% of patients achieving a confirmed partial response and a majority sustaining that response for at least a year.27PubMed Central. Selumetinib in Children with Inoperable Plexiform Neurofibromas
Selumetinib is currently approved for children aged two and older with symptomatic, inoperable plexiform neurofibromas. It does not cure the tumors, and many patients need to stay on the drug to maintain the response. Side effects can include skin rash, gastrointestinal symptoms, and increases in a heart enzyme that require monitoring. Still, for children with tumors that were previously untreatable without surgery, the drug has been transformative.
Emerging Treatments for Cutaneous Neurofibromas
Selumetinib addresses plexiform neurofibromas, but the far more common cutaneous type has had few options beyond surgical removal, which is impractical when someone has dozens or hundreds of tumors. A topical approach is now being explored. A phase 2a trial of NFX-179, a gel containing a MEK inhibitor designed to work locally and then break down quickly in the body, showed significant inhibition of the target pathway within cutaneous neurofibromas along with excellent safety.28PubMed Central. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1 A topical treatment that could shrink individual skin tumors without the side effects of a systemic drug would fill a gap that patients have been asking about for years.
Further out on the research horizon, scientists are exploring ways to directly fix the underlying genetic defect. Approaches under investigation include replacing the missing gene using viral delivery systems, repairing the DNA itself with CRISPR technology, and using RNA-based strategies to coax cells into producing functional neurofibromin.29PubMed Central. Mutation-Directed Therapeutics for Neurofibromatosis Type I None of these are close to clinical use, but laboratory work has already demonstrated that CRISPR-based editing of the NF1 gene in rat sensory neurons can successfully knock out neurofibromin expression, providing proof of concept that gene-level intervention is technically feasible.30PubMed Central. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide
Pain in Neurofibromas
Pain is one of the most debilitating and least understood aspects of living with neurofibromas. Patients report chronic pain that can range from localized tenderness over individual tumors to diffuse, burning neuropathic pain that does not correlate neatly with tumor size or location. Despite being nearly universal among NF1 patients, pain has been severely understudied compared to tumor growth and malignant transformation, with most early information coming from scattered case reports rather than systematic investigation.31PubMed Central. Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment
The sources of pain are multiple. Tumors can directly compress nerves. The inflammatory microenvironment within neurofibromas generates chemicals that sensitize nearby nerve endings. And there appear to be changes in how pain signals are processed at the spinal cord level that amplify the problem. Interestingly, the CRISPR research mentioned earlier also identified a specific protein target linked to NF1-related pain, and a drug called (S)-lacosamide was able to reverse pain behaviors in the experimental model, opening a potential new avenue for treatment beyond standard painkillers.32PubMed Central. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide
Pediatric Considerations
NF1 typically manifests in childhood, and plexiform neurofibromas in particular tend to cause problems early. A study of children with NF1 found that plexiform neurofibromas cause clinical deficits even in young children, and the authors recommended early detection and regular MRI monitoring to estimate growth trajectory and anticipate complications before they become severe.33The Journal of Pediatrics. Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Frequency and Associated Clinical Deficits Because tumor growth is fastest in younger patients, the window for intervention is often narrower than families expect.
The availability of selumetinib has changed the pediatric landscape significantly. Before 2020, children with inoperable plexiform neurofibromas had essentially no medical options. Now, treatment decisions involve balancing the drug’s long-term side-effect profile against the consequences of letting a tumor grow during the period when it is most active. An Italian expert consensus emphasized the importance of whole-body MRI to assess internal tumor burden, standardized imaging protocols so that scans can be compared over time, and risk-adapted surveillance strategies tailored to individual patients.34PubMed Central. Management of plexiform neurofibromas in neurofibromatosis type 1: An Italian Delphi consensus
The Financial Weight of the Disease
Living with NF1 and neurofibromas is expensive. A U.S. study comparing adults with NF1-associated plexiform neurofibromas to matched controls found that average total healthcare costs were roughly $34,400 per patient per year for the NF1 group versus about $6,100 for controls, a ratio of more than four to one.35PubMed Central. Characteristics, treatment patterns, healthcare resource use, and costs among adult patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas in the United States Canadian data tells a similar story: people with NF1 had roughly three times the healthcare costs of matched controls, were hospitalized at more than twice the rate, and were nearly three times as likely to receive disability benefits.36PubMed Central. Healthcare utilization patterns and costs related to neurofibromatosis 1 in Ontario, Canada
These costs accumulate across a lifetime. NF1 patients require repeated imaging, surgical procedures, specialist visits, and increasingly, ongoing medication. Lost workdays from emergency visits and hospitalizations add indirect costs that rarely show up in clinical analyses but weigh heavily on patients and families.37PubMed Central. Clinical characteristics and healthcare burden of neurofibromatosis type 1 in Saudi Arabia: a single centre experience
How Researchers Model the Disease
Progress in understanding neurofibromas and testing new drugs depends heavily on having good laboratory models, and recent advances here have been striking. Researchers have now used patient-derived stem cells to grow tumors that closely resemble human neurofibromas. In one approach, stem cells carrying NF1 mutations were coaxed into becoming Schwann-like cells and then implanted near mouse nerves; cells that had lost both copies of the NF1 gene formed genuine neurofibromas, while cells with one working copy did not. This work also pinpointed the specific cell type from which neurofibromas originate, providing a platform for testing potential drugs on tumors that faithfully mimic the human disease.38PubMed Central. Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins
A complementary model used three-dimensional cell clusters called “neurofibromaspheres,” made by combining mutant Schwann cells with fibroblasts taken from actual patient tumors. When these clusters were transplanted onto mouse nerves, they consistently produced tumor-like growths that recapitulated the cellular diversity seen in real plexiform neurofibromas, including Schwann cells at varying stages of maturity.39PubMed. Modeling iPSC-derived human neurofibroma-like tumors in mice uncovers the heterogeneity of Schwann cells within plexiform neurofibromas These models allow researchers to study the disease and test candidate therapies in a system far closer to human biology than traditional cell cultures.